Flamma SpA (“Flamma”), a preeminent Contract Development and Manufacturing Organization (CDMO) that develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, is proud to announce that it has entered into an agreement with Gilead earlier this year to be part of the network of manufacturers contributing to the Veklury® (remdesivir) supply chain.
Flamma will continue to use its sites in Italy and China to support the need for necessary compounds in an effort to help COVID-19 patients in need.
“Covid-19 hit very close to home as Flamma is located in the Bergamo, one of the most affected areas in Italy. Our facility in Dalian, China remained in full operation after the extended Chinese New Year after adding proper precautions to protect the safety and health of its employees,” noted Gian Paolo Negrisoli, CEO. “Our Italian team members utilized the protocols learned from our Chinese team and instituted them in Italy. This allowed our teams there to continue to support our customers with little to no interruption to the supply chain”.
The Flamma team has strived to provide continuous manufacturing support for remdesivir, maintaining timelines for current and upcoming projects due to the global and local needs. “This pandemic brought forth many challenges but Flamma responded to all of them with dedication and a team spirit by working tirelessly to be a part of the pharmaceutical supply chain to help those in need” notes Kenneth Drew, Ph.D., VP Flamma, USA.
During the Covid-19 crisis, Flamma teams in Italy and China have continued production of important molecules that are critical to help fight the virus. The Italian team hung a sign reading #MOLAMIA which means ‘Don’t Give Up’. Flamma doesn’t give up. This is another example of the commitment, made to not only customers but employees, to be a first-class organization. Flamma is very proud of the opportunity to support Gilead and remdesivir in the fight against Covid-19, and will continue to do all it can to be active partner in the development of breakthrough treatments.
